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A Novel Class of Tests for the Detection of Mitochondrial DNA–Mutation
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and 2Department of Medicine, Hypertension Section, Boston University School of Medicine, Boston
We develop a novel class of tests to detect mitochondrial DNA (mtDNA)–mutation involvement in complex diseases
by the study of affected pedigree members. For a pedigree, affected individuals are first considered and are then
connected through their relatives. We construct a reduced pedigree from an original pedigree. Each configuration
of a reduced pedigree is given a score, with high scores given to configurations that are consistent with mtDNA-
mutation involvement and low scores given to configurations that are not consistent with mtDNA-mutation in-
volvement. For many pedigrees, the weighted sum of scores of the pedigrees is calculated. The tests are formed by
comparing the observed score with the expected score under the null hypothesis that only nuclear autosomal
mutations are involved. We study the optimality of score functions and weights under the heterogeneity model
without phenocopies. We also develop a method to estimate the contribution that mtDNA mutations make if they
are involved under a heterogeneity model. Finally, we apply our methods to three data sets: Leber hereditary optic
neuropathy, a disease that has been proved to be caused by mtDNA mutations; non–insulin-dependent diabetes
mellitus (NIDDM); and hypertension (HTN). We find evidence of mtDNA-mutation involvement in all three diseases.
The estimated fraction of patients with NIDDM due to mtDNA-mutation involvement is 22% (95% confidence
interval [CI] 6%–38%). The fraction of patients with HTN potentially due to mtDNA-mutation involvement is
estimated at 55% (95% CI 45%–65%).
Introduction
mtDNA mutations have been found to cause various
rare diseases, such as Leber hereditary optic neuropa-
thy (LHON [MIM 535000]), Kearns-Sayre syndrome,
and NARP (neurogenic muscle weakness, ataxia, and
retinitis pigmentosa) (Wallace 1994, 1995). mtDNA
mutations have also been found to be associated with
common diseases, such as non–insulin-dependent dia-
betes (NIDDM [MIM 125853]) (Ballinger et al. 1992;
Reardon et al. 1992; van den Ouweland et al. 1992;
Kadowaki et al. 1994) and Alzheimer disease (Davis et
al. 1997). Recently, the involvement of mtDNA muta-
tions has been suggested in hypertension (HTN [MIM
145500]) (DeStefano et al. 2001). As we continue to
understand more about the genetic basis of common
diseases and mitochondrial genetics, it is suspected that
mtDNA mutations will be found to play a role in many
common diseases (Wallace 1992).
The available statistical methods are not adequate
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for the testing of mtDNA-mutation involvement and for
the study of contributions that mtDNA mutations make
to complex diseases. Ottman et al. (1988) have pro-
posed an epidemiological method to identify excess ma-
ternal inheritance of epilepsy in nuclear families. Mili
et al. (1996) have extended this method to screen for
excess maternal inheritance in extended pedigrees. Mc-
Mahon et al. (1995) have found that there were more
affected mothers than affected fathers for the probands
in the bipolar pedigrees that they studied; they also hy-
pothesized that mtDNA mutations may be involved in
bipolar affective disorder. These methods split large
pedigrees into nuclear families, and the information on
mtDNA-mutation involvement from large pedigrees is
not adequately considered. Schork and Guo (1993) have
presented a general framework for segregation analysis
to test mtDNA-mutation involvement. Recently, Haghi-
ghi and Hodge (2002) have provided a likelihood-based
method to test for parent-of-origin effects in complex
diseases. The likelihood-based approaches require as-
sumptions about the mode of inheritance of the disease
of interest and about the interactions between nuclear
and mtDNA mutations; these assumptions are generally
not known. Sun et al. (1998) have studied the statistical
properties of a test by comparing the risk carried by
one type of relative in the mitochondrial lineage of the
probands with the risk carried by the same type of rel-
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Figure 1 A reduced pedigree constructed from a true pedigree
that includes an affected grandparent and an affected grandchild. a,
True pedigree. b, Reduced pedigree. Construction of the reduced ped-
igrees is as follows: (i) married-in individuals (2 and 5) are removed;
(ii) individual 4 is labeled as affected, because individuals 1 and 6 are
connected through individual 4; (iii) the sibship consisting of individ-
uals 6 and 7 is labeled with a diamond; and (iv) individual 3 is removed,
to obtain the reduced pedigree. Individuals 1 and 4 are the informants.
ative in the nonmitochondrial lineage. The mitochon-
drial lineage of a proband is defined as the relatives who
share the same mtDNA as the proband when homo-
plasmic mtDNA transmission is assumed; the other rel-
atives form the nonmitochondrial lineage. Sun et al.
(1998) found that, under the heterogeneity model, in
which a disease is caused by either nuclear autosomal
mutations or mtDNA mutations, the power of the test
increases as the relationship between the relatives and
the probands becomes distant; however, they did not
provide methods to combine information from different
types of relatives.
In the present study, we develop a novel class of tests
to detect mtDNA-mutation involvement in complex dis-
eases by the study of affected pedigree members. These
tests are applicable to pedigrees ascertained through
various sampling schemes, such as families with affected
sibling pairs or families with multiple affected individ-
uals, as long as the inclusion and/or exclusion of pedi-
grees does not depend on the sex of affected individuals.
The tests do not assume the mode of inheritance of the
disease, although the power of the tests certainly de-
pends on the mode of inheritance. In this sense, the tests
developed here are nonparametric. We also develop
methods to combine information from different ped-
igrees. Our approach is similar to that proposed by
Weeks and Lange (1988, 1992), Whittemore and Hal-
pern (1994), and Teng and Siegmund (1997) for link-
age studies of nuclear mutations when affected pedi-
gree members are included.
First, we present the class of statistical tests, which
depend on score functions defined for the relationship
among affected individuals. Then, we study the op-
timality of score functions under the heterogeneity
model, which assumes that the disease can be caused
by either autosomal mutations or mtDNA mutations.
We also present methods to estimate the contribution
of mtDNA mutations, under the heterogeneity model,
once evidence has been found for their involvement.
Finally, we apply our tests to simulated data and real
data on LHON (which has been proved to be related
to mtDNA mutations), NIDDM, and HTN.
Tests
To avoid pedigrees with disease due to different mu-
tations, we consider only those pedigrees in which in-
dividuals who marry into the pedigrees and their first-
degree relatives are not affected. If that happens, then
we remove affected married-in individuals and their de-
scendants from the study.
Score Function and Test Statistic with One Pedigree
For a given pedigree, we construct another pedigree
as follows:
1. Remove the married-in individuals.
2. Connect any two affected individuals through their
closest relatives and mark the individuals between
them as affected.
3. If a sibship has at least one affected individual and
none of them have affected offspring, then denote
the sibship with a diamond.
4. Remove unaffected individuals in the resulting ped-
igree.
The resulting pedigree will be referred to as a “reduced
pedigree.” Individuals having at least one descendant in
the reduced pedigree will be referred to as “informants,”
since only these individuals provide information on
mtDNA-mutation involvement. Only pedigrees with at
least two affected sibships in the reduced pedigrees are
considered in the analysis. Pedigrees with only one af-
fected sibship in the reduced pedigrees are not used. We
emphasize here that an affected sibship can contain one
or more affected individuals. Figure 1a shows a true
pedigree consisting of an affected grandparent and an
affected grandchild with an unaffected mother; the cor-
responding reduced pedigree is shown in figure 1b. Fig-
ure 2a provides an example of a pedigree with affected
cousin pairs; the corresponding reduced pedigree is given
in figure 2b. It is reasonable to assume that all members
in the reduced pedigree carry the genetic mutation(s)
responsible for the disease if it is a genetic disease. In
this sense, we include only affected pedigree members
in the present study. In complex diseases, it is often
difficult to determine unambiguously if an individual is
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Figure 2 A reduced pedigree constructed from a pedigree with
affected cousin pairs. a, True pedigree. b, Reduced pedigree. Construc-
tion of the reduced pedigrees is as follows: (i) married-in individuals
(5 and 8) are removed; (ii) individuals 3 and 4 are labeled as affected,
because individuals 6 and 9 are connected through individual 4; (iii)
the sibship consisting of individuals 6 and 7 and the sibship consisting
of individual 9 are labeled with a diamond; and (iv) individuals 1, 2,
5, and 8 are removed, to obtain the reduced pedigree. Individuals 3
and 4 are the informants.
Figure 3 The four reduced pedigrees after neutralizing the sex
of the informants corresponding to the reduced pedigree in figure 1b.
affected. For late-onset diseases, although an individual
may carry the genetic mutation, he or she may not be
affected, because he or she has not yet reached the age
of onset. The inclusion of only affected members may
reduce these problems. The reasons for consideration of
affected pedigree members are the same as those in the
linkage analysis of nuclear mutations.
We next neutralize the sex of informants. Let k be the
number of informants in the reduced pedigree. There are
possible configurations in which each informant in thek2
reduced pedigree is either male or female. For the reduced
pedigree in figure 1b, we have kp 2. The p 4 possiblek2
configurations are given in figure 3. Similarly, for the
reduced pedigree in figure 2b, k p 2, and the p 4k2
possible configurations are given in figure 4. If only nu-
clear autosomal mutations are involved and there are no
sex differences with respect to prevalence and fertility,
then these configurations should be equally probable,k2
with probability .k2
A score function is defined by giving a score toS(f )j
each of the configurations . Highk k2 f , jp 1,2, … ,2j
scores are given to configurations that are consistent
with mtDNA-mutation involvement, and low scores are
given to configurations that are not consistent with
mtDNA-mutation involvement. For example, a higher
score is given to configuration a than to the other three
configurations in figure 3. Similarly, a higher score is
given to configuration c than to the other three config-
urations. Let T be the score for a reduced pedigree with
k informants. Under the null hypothesis of only nuclear-
autosomal-mutation involvement, all the configura-k2
tions are equally likely, with probability , becausek1/2
all the informants can be either male or female with the
same probability, 1/2. The mean score for a reducedE(T)
pedigree with k informants is . ThekE(T)p 2  S(f )jfj
summation is over all the configurations. The variancek2
is .k 2 2Var (T)p 2  S (f ) [E(T)]jfj
Score Function and Test Statistic with Several
Pedigrees
Now, suppose that we have n pedigrees. We first
generate the corresponding reduced pedigrees. Sup-
pose that the n reduced pedigrees can be classified into
I classes, , with reduced pedigrees in theC ,C , … ,C n1 2 I i
ith class, . The pedigrees within…n  n   n p n1 2 I
each class have the same reduced pedigree except that
the sex of the informants may be different. Let befij
the configuration in the jth reduced pedigree of the
ith class, when and . Then,jp 1,2, … ,n ip 1,2, … ,Ii
are independent identically distrib-S(f ), jp 1,2, … ,nij i
uted random variables and have the same distribution
under the null hypothesis of only nuclear-autosomal-
mutation involvement. Let T be the weighted sum of
scores for all the pedigrees with weight for pedigreeswi
in the ith class; that is,
I ni
Tp w S(f ) . i ij
ip1 jp1
The idea is to reject the null hypothesis that only nuclear
autosomal mutations are involved if T is large compared
with its mean.
We consider the following statistic:
T E(T)
Tp ,Var (T)
where and are the expectation and var-E(T) Var (T)
iance of T under the null hypothesis of only nuclear-
autosomal-mutation involvement. From equations (1)
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Figure 4 The four reduced pedigrees after neutralizing the sex of the informants corresponding to the reduced pedigree in figure 2b
and (2), we have andIE(T)p  w n E(T ) Var (T)pi i iip1
.I 2 w n Var (T )i i iip1
tends to the standard normal distribution, with meanT
0 and variance 1, when tend to . Thus,n , ip 1,2, … ,Ii
it is relatively easy to obtain the significance level for an
observed T. When is not large and normal approxi-ni
mation is in doubt, we can use the following formula to
calculate the significance level for an observed T:
I ni
IS n ki iip1ap P(f )p N(T)2 , (3)  ij
ip1 jp1
where is the number of informants in the reducedki
pedigree for the ith class and is the number ofN(T)
configurations such that{f , jp 1,2, … ,n , ip 1,2, … ,I}ij i
is at least T. Equation (3) holds becauseI ni  w S(f )i ijip1 jp1
and the summation in the middle is over allkiP(f )p 2ij
the configurations such that is at least T.I ni  w S(f )i ijip1 jp1
Different score functions and weights give different
tests. The problem becomes how to choose score func-
tions and weights. We will consider the choice of score
functions and weights under the heterogeneity model in
the next section, “Score Functions and Power Analysis.”
The resulting statistics have several features:
First, as shown above, the tests permit calculation of
exact P values when the number of pedigrees are small
and normal approximations are in doubt.
Second, because we use only affected members and
their closest relatives, the tests are applicable to pedigrees
ascertained through multiple affected members. This fea-
ture is particularly important, since many pedigrees col-
lected for linkage analysis are ascertained through mul-
tiple affected members. The tests are affected by neither
late onset nor variable onset of a disease, although the
power does depend on these factors. The tests are valid
as long as the ascertainment does not depend on the sex
of individuals to be included. However, we note that
different rates of participation in a study, as well as
recall bias of the affection status for males and females,
can invalidate the results.
Third, the separation of probability distribution and
score functions for the configurations of reduced pedi-
grees is another feature of the tests. This feature makes
it possible to choose appropriate probability distribution
and score functions under different scenarios. For ex-
ample, we can modify the score function according to
different assumptions about the etiology of the disease.
Thus, if we were to assume no phenocopies, we might
give a high score to the configuration in which all affect-
ed informants are females and a common low score to
other configurations. If we were to allow phenocopies,
we might let the score of a configuration be a decreasing
function of the number of different possible types of
mtDNAs among the affected individuals.
Fourth, the tests combine information from different
pedigrees. A suitable weighting scheme for different
classes of pedigrees allows us to give different weights
according to each class’s importance to the goal of de-
tecting mtDNA-mutation involvement. In the next sec-
tion (“Score Functions and Power Analysis”), we show
that, under the heterogeneity model, the weights should
increase with the number of informants in a reduced
pedigree. This is consistent with our previous study, in
which distant relatives had higher power than close rel-
atives under the heterogeneity model (Sun et al. 1998).
As with other tests for excess maternal inheritance,
the significance of the tests does not lead us directly to
the conclusion that mtDNA mutations are involved in
the etiology of the disease. There are other confounding
factors that can lead to the significance of the test: X
linkage, maternal imprinting, differential prevalence of
the disease among males and females, differential fertility
for affected males and females, intrauterine effect, and
other genetic or environmental factors can all lead to
the rejection of the null hypothesis. Some of these factors
can be circumvented through the tests, and some cannot.
Differential prevalences and fertilities among males
and females can be circumvented by changing the prob-
ability distribution for the configurations of reduced
pedigrees. If the prevalence of the disease among males,
, and the prevalence of the disease in females, , arep pm f
different, then we can incorporate this by defining the
probability for a configuration with k affected mothers
and affected fathers asn k
k nkp pf m( )nk .( ) ( )p  p p  pf m f m
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Similarly, we can incorporate differential fertilities and
recall bias for males and females into the probability dis-
tribution. However, we emphasize that and have top pm f
be known to be incorporated into our model.
Using reduced pedigrees comprising three or more
generations, we can distinguish between maternal im-
printing and mitochondrial inheritance. For example,
for the four configurations in figure 3, let p 1,S(a)
p 1, p 3, p 1. Then, under theS(b) S(c) S(d)
hypothesis of only nuclear autosomal mutations and no
imprinting, the four configurations are equally likely,
with probability 1/4. The mean score of such reduced
pedigrees is (1  1  3  1)/4p 1. For an autosomal
maternally imprinted gene, we can see only configura-
tions a and c, since males do not transmit the disease to
their offspring (Sleutels et al. 2000). The two configu-
rations have the same probability, 1/2. Suppose that the
disease can be caused by nuclear mutations, with prob-
ability 1 f, or maternally imprinted nuclear autosomal
mutations, with probability f. Then, the mean score of
one such pedigree is
f(1 3)
(1 f )(1) p 1 .
2
The two means are the same. It is highly unlikely that
the test yields significant results. In contrast, under the
heterogeneity model with autosomal and mtDNA mu-
tations, the mean score is
(1 f )(1) 1fp 1 2f 1 1 . (4)
Therefore, with a sufficient number of such reduced pedi-
grees, the test can yield significant results. Therefore,using
the above score function (eq. [4]), we eliminated the con-
founding factor due to imprinting. For other types of re-
duced pedigrees, we can similarly define score functions
so that imprinting is not a confounding factor. Note that
the above score function (eq. [4]) reduces the power of
the test when mtDNA mutations are actually involved.
Also note that we have to use reduced pedigrees with at
least three generations to distinguish between maternal
imprinting and mtDNA-mutation involvement.
Score Functions and Power Analysis
In the previous section (“Tests”), we have presented the
general idea of how to construct the class of tests. For a
given score function, the power of the corresponding test
depends on the underlying disease-transmission model.
For a given disease-transmission model, we say that test
(corresponding to a score function ) is better thanT S1 1
test (corresponding to a score function ) if is moreT S T2 2 1
powerful than under that disease-transmission model.T2
In the present section, we consider the heterogeneity
model. Let f be the fraction of pedigrees with disease
due to mtDNA mutations and let be the fraction1 f
of pedigrees with disease due to nuclear autosomal mu-
tations with no phenocopies. To consider the optimality
of score functions, we first assume that all reduced ped-
igrees are of the same class, with i informants in each
reduced pedigree. There are possible configurationsi2
for the reduced pedigrees. If a pedigree has disease that
is due to nuclear autosomal mutations, then all the con-
figurations have the same probability, . If a pedigreei2
has disease that is due to mtDNA mutations, then only
one configuration is possible; that is, all the informants
are female. Under the above assumptions, theoretical
studies have shown that the optimal score function is
to assign a high score to the configuration in which all
the informants are females and to assign a common low
score to the other configurations. The power ofk2  1
the resulting test does not depend on the specific values
of the high and low scores. Therefore, we choose the
high score to be 1 and the low score to be 1. Let Ti
be the resulting statistic for reduced pedigrees having
i informants. Under the heterogeneity model, we have
P{T p 1}p f (1 f )p ,P{T p 1}p (1 f )q ,i i i i
where and .ip p 2 q p 1 pi i i
E(T)p f (1 f )(p  q ) ,i i i
and
Var (T)p 4(1 f )q [f (1 f )p ] .i i i
We classify all reduced pedigrees with the same num-
ber, i, of informants into one class, called the ith class.
Suppose that there are I classes of pedigrees with ni
pedigrees in the ith class. Next, let us consider how to
choose the weight, , for the ith class. Recall thatwi
, where is the score for the jthI niTp  w  S Si ij ijip1 jp1
pedigree in the ith class. are indepen-S , jp 1,2, … ,nij i
dent identically distributed random variables and have
the same distribution as . Therefore,Ti
I
E(T)p w n [f (1 f )(p  q )] , i i i i
ip1
and
I
2Var (T)p 4(1 f ) w n q [f (1 f )p ] . i i i i
ip1
Let and be the mean and variance of T underE V0 0
the null hypothesis that . Then,fp 0
T E0
Tp (5)V0
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Table 1
Efficiency of Test Statistics
′f
EFFICIENCYa WHEN f IS
.00 .10 .20 .30 .40 .50 .60 .70 .80 .90 1.00
.00 1.00 .97 .93 .90 .87 .82 .81 .79 .78 .77 .77
.25 .91 .98 1.00 1.00 .99 .99 .98 .97 .96 .95 .95
.50 .84 .94 .98 .99 1.00 1.00 1.00 1.00 .99 .99 .99
.75 .79 .90 .95 .98 .99 1.00 1.00 1.00 1.00 1.00 1.00
1.00 .76 .87 .93 .96 .98 .99 .99 .99 1.00 1.00 1.00
NOTE.—Results are based on test statistics in equation (5), using different weights
when the ratio for the numbers of families with 1,′ i ′w p 1/ [f  2 (1 f )] , ip 1,2,3i
2, and 3 informants is 3:2:1.
a Calculated using equation (6), where f is the underlying fraction of individuals affected
owing to mtDNA-mutation involvement.
is approximately normal when are large.n , ip 1,2, … ,Ii
We reject the null hypothesis when
T E0
Tp  z ,aV0
for a significance level a, where is the percentilez 1 aa
of the standard normal distribution.
The power of this test is given by
If w n qip1 i i i
1 bp 1 F( I 2(1 f ) w n q [f (1 f )p ]ip1 i i i i
I 2 w n q pip1 i i i i z ,a I )2 w n q [f (1 f )p ]ip1 i i i i
where is the cumulative distribution function for theF(7)
standard normal distribution. The smaller the term inside
F is, the larger the power is. When aren , ip 1,2, … ,Ii
large, the dominant term inside F is the first one. There-
fore, the best weights, , should maximizewi
I 2( w n q )ip1 i i i
.
I 2 w n q [f (1 f )p ]ip1 i i i i
Mathematical analysis has shown that should be pro-wi
portional to .1/[f (1 f )p ]i
In reality, we do not know the actual value of f.There-
fore, we cannot use the above weights in the test. There
are several possible choices for the weights. On the one
hand, if we are interested in detecting a very small frac-
tion of mtDNA-mutation involvement, then we may
take , which gives weights ; for example,fp 0 w p 1/pi i
if there are i informants in the reduced pedigree, then
we let . On the other hand, if we are interestediw p 2i
in testing for f to be in a certain range, then we may
take f to be the middle point of that range; for example,
we may take if we are interested in testingfp 0.25
. When f is relatively large, such as ,0 ! f ! 0.5 f 1 0.5
it should be relatively easy to detect the involvement
of mtDNA mutations, and different weights may not
be very important for the power of the test.
Using the idea of Feingold and Siegmund (1997) and
Teng and Siegmund (1997), we define the “efficiency”
of a test, T, using weights as the limit of the ratiowi
between the number of pedigrees n, using test T, and
the number of pedigrees , using the optimal weightsn0
, to obtain the same power as Tw p 1/[f (1 f )p ]i i
when n tends to . Let be the fraction of ith-classl i
pedigrees. From the power function, the efficiency of a
test T with weights, , is given bywi
2I( ) w l qip1 i i i
.
I I 2{ }{ } l q /[f (1 f )p ]  w l q [f (1 f )p ]ip1 ip1i i i i i i i
(6)
Table 1 shows the efficiency of five tests using weights
with′ ′ ′w p 1/[f  (1 f )p ] f p 0,0.25,0.50,0.75,1.00i i
at different values of f when . Froml :l :l p 3:2:11 2 3
table 1, we see that the efficiency is close to 1 when ′f
is close to f. When , the efficiency decreases rap-′f p 0
idly, and the efficiency is ∼80% when . Whenf 1 0.50
, the efficiency is always 191%, and the effi-′f p 0.25
ciency is 195% when . When , the effi-′f 1 0.05 f p 1
ciency is !87% when .f ! 0.10
We use simulations to confirm the theoretical results.
In the simulations, reduced pedigrees each having ini
informants, with , were simulatedip 1,2,3 n  n  n1 2 3
according to the heterogeneity model. Twenty sets of sim-
ulations, corresponding to by step 5,n ,n ,n p 5–201 2 3
were done. Five test statistics, corre-T ,kp 1,2,3,4,5k
sponding to weights ,′ ′w p 1/[f  (1 f )p ] ip 1,2,3i i
for , respectively, were stud-′f p 0,0.25,0.50,0.75,1.0
ied. First, the critical values of thec ,kp 1,2,3,4,5k
five test statistics for significance levelT ,kp 1,2, … ,5k
were found, respectively, by 10,000 repetitionsap 0.05
under the null hypothesis of only nuclear-autosomal-mu-
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Table 2
Simulated Power of Five Tests T ,kp 1,2, … ,5k
TEST
STATISTIC
APPROXIMATE POWERa WHEN f b IS
.05 .10 .15 .20 .25 .30 .35 .40 .45
T1 .10 .20 .32 .45 .59 .73 .83 .90 .95
T2 .12 .22 .35 .50 .64 .77 .88 .93 .97
T3 .12 .21 .33 .48 .62 .76 .86 .92 .97
T4 .12 .21 .33 .48 .62 .76 .86 .92 .97
T5 .07 .13 .22 .35 .49 .64 .77 .86 .93
NOTE.—Results are based on test statistics in equation (5), using
different weights ′ i ′w (k)p 1/ {f (k) 2 [1 f (k)]} , kp 1,2, … ,5,i
. Type I error rate is set at .05.ip 1,2,3
a Based on 10,000 simulations consisting of 15, 10, and 5 reduced
pedigrees with 1, 2, and 3 informants, respectively.
b True fraction of individuals affected owing to mtDNA-mutation
involvement.
tation involvement. Once the critical values were found,
the same number of pedigrees were simulated under the
heterogeneity model for by step 0.05, forfp 0.05–0.45
10,000 times each. In each simulation, the five statistics
were calculated. The power of test was the fraction ofTk
times . Table 2 gives the powers ofT  c ,kp 1,2,3,4,5k k
the five tests for , , and ,n p 15 n p 10 n p 5 fp1 2 3
by step 0.05. Table 2 is typical in that, in most0.05–0.45
of the 20 sets of simulations, was the best test statistic,T2
followed by , , and . almost always had theT T T T3 4 1 5
least power in the range of . This is consistent0 ! f ! 0.5
with our theoretical predictions.
Estimating the Contribution of mtDNA Mutations
In the previous sections, we have considered the problem
of the testing of mtDNA-mutation involvement in a dis-
ease. Once evidence of mtDNA-mutation involvement
has been found, it is important to estimate the contri-
bution that mtDNA mutations make to the disease. We
use an attributable fraction to measure this contribution.
The attributable fraction due to mtDNA mutations is
defined as the difference between the prevalence of the
disease among the general population and the prevalence
among individuals without the mtDNA mutations di-
vided by the prevalence of the disease among the general
population. Under the heterogeneity model, the attrib-
utable fraction due to mtDNA mutations is equal to the
fraction of individuals affected owing to mtDNA mu-
tations (Khoury et al. 1993). In the present section, we
propose a method to estimate the attributable fraction
under the heterogeneity model without phenocopies,
using affected members only.
First, we assume that all reduced pedigrees are of the
same class, with i informants in the reduced pedigrees.
Let and f be the fraction of pedigrees with diseaseip p 2i
due to mtDNA mutations. Then, the probability of hav-
ing pedigrees with score 1 and pedigrees withk n  ki i i
score 1 among randomly sampled pedigrees isni
k n ki i i( )L (f )p n k [f (1 f )p ] [(1 f )q ] ,i i i i i
where . The maximum-likelihood estimateq p 1 pi i
of f is
k pi i′f p  . (7)
n q qi i i
When the right-hand side of equation (7) is !0, we take
. Because , is always 1. When ,′ ′f p 0 k  n f k p ni i i i
. is an unbiased estimator of f, with mean and′ ′f p 1 f
variance
(p  fq )(1 f )i i′ ′E(f )p f, Var (f )p .
n qi i
The CI of f can be approximated by1 a
′ ′(p  f q )(1 f )i i′ f  z .a n qi i
Now, suppose that there are I classes of reduced ped-
igrees, with i informants in the ith class, .ip 1,2, … ,I
If the estimations of f by use of different classes of re-
duced pedigrees are not statistically different, then we
combine the information from different classes as fol-
lows. Suppose that there are pedigrees in the ith classni
and of them have score 1. Then, the likelihood func-ki
tion is the product of the likelihood function across all
the classes; that is,
I
L(f )p L (f ) i
ip1
I
k n ki i i( )p n k [f (1 f )p ] [(1 f )q ] . i i i i
ip1
The maximum point of this likelihood functions satisfies
the following equation:
II  (n  k )ip1 i iq ki i p . (8)
p  q f 1 fip1 i i
When , equation (8) does notI I (q k /p ) !  (n  k )i i i i iip1 ip1
have a solution, and we let . Otherwise, equation′f p 0
(8) has a unique solution that determines the maximum-
likelihood estimation of f. By use of Fisher’s information
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Table 3
Numbers of Pedigrees with Scores 1 and 51 and Estimation for Contributions
of mtDNA Mutations—among the NIDDM Pedigrees
NO. OF INFORMANTS
NO. OF PEDIGREES
′f j ′f 95% CITotal Score 1
a Score 1a
1 83 51 (41.5) 32 (41.5) .23 .11 .02–.44
2 21 8 (4.25) 13 (16.75) .17 .14 0–.45
3 5 3 (.6) 2 (4.4) .54 .25 .05–1
4 1 0 (.06) 1 (.9)
5 1 0 (.03) 1 (1.0)
Combined 111 62 49 .22 .08 .06–.38
a Expected numbers of families under the null hypothesis of no parent-of-origin
effect are given in parentheses.
theory (Bickel and Doksum 2001), the approximate vari-
ance of is given by I′ 2f j p 1/ [n q /(p  fq )(1 f )]′f i i i iip1
when are large. The CI is ap-n , ip 1,2, … ,I 1 ai
proximately .′f  z j ′a f
Applications
In the present section, we apply our proposed tests and
the estimation method to three data sets: LHON, a
disease that has been proved to be related to mtDNA
mutations; NIDDM; and HTN. Our purpose is to see
if the tests can detect the mtDNA-mutation involve-
ment in LHON. Then, we want to see if mtDNA mu-
tations are involved in NIDDM or HTN.
Example 1. LHON
As did Mili et al. (1996), we used pedigrees from
studies published before the first mtDNA mutation that
causes LHON was identified (Wallace et al. 1988; Singh
et al. 1989). These pedigrees may be regarded as a ran-
dom sample of the LHON-affected pedigrees, because
investigators only speculated on the mode of inheritance
of LHON. We defined the disease as present if an in-
dividual was affected and as absent otherwise. Only ped-
igrees with at least two affected sibships were useful for
our analysis. We obtained a total of 18 pedigrees from
the literature (Kwittken and Barest 1958; Wilson 1963,
1965; Went 1964; Adams et al. 1966; Wallace 1970;
Nikoskelainen et al. 1977, 1987; McLeod et al. 1978;
Muller-Jensen et al. 1978; Johnston et al. 1979; Cotticelli
et al. 1984; Novotny et al. 1986). Then, we constructed
the corresponding reduced pedigrees according to the
methods given above. We found seven reduced pedigrees
with 4 informants, four reduced pedigrees with 1 in-
formant, two reduced pedigrees with 3 informants, and
one reduced pedigree each with 2, 6, 8, 15, and 18 in-
formants. In all the reduced pedigrees, the informants
are females. If we do not consider that males are more
likely to be affected than females, then, under the null
hypothesis that only nuclear autosomal mutations are
involved, the probability of seeing the configurations is
, which is extremely[(4#7)(1#4)(3#2)2681518] 872 p 2
small. If we consider that males are more likely to be
affected than females, then this probability is even smaller.
Therefore, we reject the null hypothesis that only nuclear
autosomal mutations are involved in LHON. Actually, all
reduced pedigrees are consistent with mtDNA-mutation
involvement.
We used equation (8) to estimate the contribution
of mtDNA mutations. Because all the reduced pedi-
grees have score 1, the maximum-likelihood estima-
tion of f is equal to 1. Almost 100% of the LHON
cases are due to mtDNA mutations. Molecular stud-
ies have found that mutations at nucleotide positions
11778, 3460, and 14484 in the mitochondrial genome
account for 197% of LHON cases worldwide. Our
results are consistent with molecular studies.
Example 2. NIDDM
Many studies have found excess maternal inheritance
for NIDDM (for a recent review, see Alcolado et al.
2002). In the present article, we applied our tests to an
NIDDM data set provided by the National Diabetes As-
sociation GENNID (Genetics of NIDDM) Study (Raffel
et al. 1996). The phenotypes of individuals in the GEN-
NID data set were carefully defined by historical data,
physical-examination findings, and basic metabolic and
biochemical testing. (For details on data collection, see
Raffel et al. 1996.) From population data, no significant
differences were observed for the prevalence of NIDDM
between males and females, although the prevalence
of NIDDM can be very different among major ethnic
groups. We used 161 pedigrees in this data set. We con-
structed the reduced pedigrees according to the method
described above. Table 3 gives the number of pedigrees
with scores 1 and1 for each class of reduced pedigrees
with one to five informants; in parentheses, we also give
the expected number of pedigrees with scores 1 and 1
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for each class of pedigrees under the null hypothesis of
only nuclear autosomal mutations. For reduced ped-ni
igrees with i informants, the expected number of pedi-
grees with score 1 is . From table 3, we see thati2 # ni
there are always more reduced pedigrees with score 1
than expected for reduced pedigrees with one, two, and
three informants. In this data set, there is only one re-
duced pedigree each with four and five informants, and
we cannot see the pattern here. This observation is con-
sistent with mtDNA-mutation involvement or other ma-
ternal effects for NIDDM.
We then applied our statistics to reduced pedigrees
with one, two, and three informants with weights
. We choose theseiw p 1/[0.25 (0.75 # 2 )], ip 1,2,3i
weights on the basis of our results in a previous section
(“Score Functions and Power Analysis”). The score for
all the pedigrees is 19.11. Simulations showed the P
value to be ∼.0009. We also used other weights w pi
for reduced ped-′ ′ i ′1/[f  (1 f )2 ], f p 0,0.5,0.75,1.0
igrees with one, two, and three informants; the corre-
sponding P values are .0005, .0005, .0015, and .0026,
respectively. Thus, the null hypothesis can be rejected
using any weights. It should be noted that the P values
are higher for than for .′ ′f p 0.75,1.0 f p 0,0.25,0.5
Next, we studied the contribution that mtDNA mu-
tations make to NIDDM. Using the above methods, we
estimated the fraction of pedigrees with disease due to
mtDNA mutations, its SD, and the corresponding 95%
CI by using both the classes of pedigrees with one, two,
and three informants separately and the combined data
set. The results are given in the last three columns of
table 3. For example, using the 83 reduced pedigrees
with one affected informant, we estimate the fraction of
pedigrees with disease due to mtDNA mutations to be
23% (95% CI 2%–44%). The numbers of reduced ped-
igrees with two and three informants are small, 21 and
5 pedigrees, respectively. The estimation may not be ac-
curate. Although the three estimations seem different,
the three 95% CIs overlap in a large region (5%–45%).
The difference may be caused by the small sample size
in the last two classes of pedigrees. We then combined
the three classes by using the above proposed method.
Using the combined data set, we estimated the fraction
of pedigrees with disease due to mtDNA mutations to
be 22% (95% CI 6%–38%). Although the point esti-
mation of this fraction was roughly the same as that
using only reduced pedigrees with one informant, the
95% CI was much narrower than the one using only
reduced pedigrees with one informant. Molecular studies
have found that 5% of patients with NIDDM harbor
pathological mtDNA mutations, and our results are con-
sistent with molecular studies. Furthermore, our results
indicate that more NIDDM cases may be found to be
due to mtDNA mutations.
Example 3. HTN
HTN, presently defined in the United States as a
blood pressure value 140/90 mmHg, represents the
higher end of the blood pressure distribution in the
general population. Several investigators noted signif-
icant mother-offspring correlations in blood pressure
levels and little or no father-offspring correlations,
indicating maternal effect. Recently, DeStefano et al.
(2001) studied the contributions from mothers and
fathers to HTN in whites and African Americans. In
the study, hypertensive probands were ascertained
without respect to family history of HTN from clinics
at the Boston Medical Center and collaborating sites
in Greece. Individuals were classified as affected with
primary HTN on the basis of standard clinical criteria
(i.e., unequivocal elevation of blood pressure 140/90
on at least three different occasions or chronic hyper-
tensive treatment with previously documented high
blood pressure in the medical records) and on the basis
of the absence of findings suggestive of HTN secondary
to organic causes. Probands were identified by a clinic
physician. By consideration of these individuals as in-
dex subjects, the pedigrees of multigeneration families
with HTN were collected. Data collected on relatives
included date of birth, date and cause of death (if ap-
plicable), hypertensive status, age at diagnosis (for hy-
pertensive individuals), and risk-factor information.
DeStefano et al. (2001) found that, among parents with
known hypertensive status, the fraction of affected
mothers is significantly higher than the fraction of af-
fected fathers among hypertensive probands of African
Americans, U.S. whites, and Greek whites. They also
studied the affection status of siblings of the probands
and found that the siblings of probands with mother
only affected are more likely to be affected than are
the siblings of probands with father only affected in
Greek whites. However, no significant difference was
found in African Americans and U.S. whites. Molecular
studies have found significant associations between
some pathological mtDNA mutations and HTN-as-
sociated end-stage renal disease (Watson et al. 2001).
We applied our method to the HTN data sets for
whites and African Americans, respectively (DeStefano
et al. 2001). Individuals with unknown status were
treated as unaffected. (For details on data collection,
see DeStefano et al. 2001.) A total of 350 white ped-
igrees and 98 African American pedigrees are avail-
able. The numbers of noninformative pedigrees are 172
and 43 for whites and African Americans, respectively.
The fraction of noninformative pedigrees in whites
(172/350 [49%]) is very close to the fraction of noninfor-
mative pedigrees in African Americans (43/98 [44%]).
Among the informative pedigrees, the numbers of ped-
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Table 4
Numbers of Pedigrees with Scores 1 and 51 and Estimation for Contributions of mtDNA
Mutations—among the Pedigrees with HTN
NO. OF INFORMANTS
NO. OF PEDIGREES
′f j ′f 95% CITotal Score 1
a Score 1a
Whites:
1 178 133 (89) 45 (89) .49 .065 .36–.62
2 10 8 (2.5) 2 (7.5) .73 .17 .40–1.00
African Americans:
1 55 42 (27.5) 13 (27.5) .53 .12 .30–.76
2 9 9 (2.25) 0 (7.75) 1.0 … .72–1.00
Whites and African Americans:
1 233 175 (116.5) 58 (116.5) .50 .057 .39–.61
2 19 17 (4.75) 2 (14.25) .86 .094 .68–1.00
Combined 252 192 60 .55 .05 .45–.65
a Expected numbers of families under the null hypothesis of no parent-of-origin effect are given
in parentheses.
igrees with different numbers of informants and with
scores 1 and 1 are given in table 4. Among the pedi-
grees with one informant, the fraction of pedigrees with
mother only affected in whites (133/178 [75%]) is very
close to that in African Americans (42/55 [76%]). We
then applied our test statistics to the reduced pedigrees,
and the P value was ! when any weights were used.710
Thus, maternal effect for HTN is much stronger than
that for NIDDM.
Assuming that a fraction f of HTN cases are caused
by mtDNA mutations and that others are caused by
nuclear autosomal mutations, we can use our method
to estimate f. The estimated values of f obtained using
data on families with one or two informants for whites
and African Americans are given in table 4. The esti-
mated values of f obtained using families with two in-
formants vary widely and seem very different from the
estimated values of f obtained using reduced pedigrees
with one informant. This may be due to the small num-
ber of families with two informants. The 95% CIs of f
overlap with each other. Thus, we combine the data to
give an overall estimate of f. Using all the data with one
or two informants in both whites and African Amer-
icans, we estimate f to be 55% (95% CI 45%–65%).
Discussion
In the present article, we have developed a novel class
of statistics to test mtDNA-mutation involvement in a
disease. The class of tests has several features. First, the
tests do not depend on the mode of inheritance of the
disease, although their power certainly differs according
to different modes of inheritance. Second, they are ap-
plicable to pedigrees ascertained through multiple af-
fected members. This feature is particularly important,
since many pedigrees collected for linkage studies were
ascertained through multiple affected members. Third,
they combine information from different pedigrees by
choosing weights for different reduced pedigree struc-
tures on the basis of their importance to the goal of
finding mtDNA-mutation involvement. Finally, the tests
can be adapted to circumvent some of the confounding
factors, such as differential prevalence and fertility (if
they are known) among affected males and females.
The class of tests is intended to be nonparametric in
that it does not depend on the mode of inheritance of
the disease and other parameters, such as prevalence
and penetrance of the mutant alleles. The power of the
tests certainly depends on these parameters. In the pres-
ent study, we considered the heterogeneity model with-
out phenocopies. Under this model, we studied the op-
timality of score functions and weighting schemes. With
reduced pedigrees of the same type, we found that the
optimal score function is to give a high score to the
configuration in which all the informants in the reduced
pedigree are females and to give a common low score
to other configurations. The power of the resulting test
does not depend on the particular values of the high
and low scores. Therefore, we give score 1 to the former
and score1 to the latter. We also studied the efficiency
of different weighting schemes. Once evidence has been
found for mtDNA-mutation involvement, we propose
a method to estimate the contribution of mtDNA mu-
tations. Although our assumption based on the model
without phenocopies is strong, the results obtained in
the present study should be useful for well-designed
studies, such as the GENNID Study (Raffel et al. 1996).
The present study is also useful in that it provides in-
sights into how to choose score functions according to
different assumptions about the disease-transmission
mechanism.
There are several limitations of the proposed tests.
First, although the tests are valid if the ascertainment
scheme does not explicitly include or exclude individu-
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als on the basis of sex, differential rates of participa-
tion in a study and recall bias between males and fe-
males can all lead to misleading results. Differential
prevalences of the disease and different fertility among
affected males and females can be incorporated into
our model if they are known; however, they are gen-
erally not known, and these parameters have to be es-
timated from the data. Second, the statistically signifi-
cant results do not lead us directly to the conclusion of
mtDNA-mutation involvement in a disease. Some con-
founding factors can be tested using other statistics, and
some cannot. Third, we assumed a heterogeneity model
in the present study. For complex diseases, such as di-
abetes and HTN, the disease model can be much more
complicated, and the heterogeneity model may not be
valid. If nuclear and mtDNA mutations interact with
each other in a disease, then we will see excess maternal
inheritance, as well as father-to-offspring transmissions
of the disease. The father-to-offspring transmissions are
not counted toward mtDNA-mutation involvement un-
der the heterogeneity model, and, thus, the true fraction
of affected individuals with mtDNA-mutation involve-
ment is underestimated on the basis of the heterogeneity
model. Therefore, the fraction of affected individuals
with mtDNA-mutation involvement as estimated on the
basis of the heterogeneity model represents a lower
bound for its true value. Fourth, the attributable frac-
tion estimated in the present study may not apply to
the whole population, but only to pedigrees that meet
the inclusion criteria. As pointed out by Whittemore
and Halpern (2001), the definition and interpretation
of the proportion of families segregating a nuclear var-
iation of interest makes sense only under very strict—
and, most likely, unrealistic—assumptions. The same
concerns apply here to heterogeneous diseases involving
both nuclear and mitochondrial mutations. Finally, the
methods developed in the present study can test only if
mtDNA mutations are involved in a disease of interest.
They cannot be used to distinguish between the contri-
butions of inherited mtDNA mutations and a more gen-
eral contribution of certain common mtDNA haplotypes.
We have applied our test statistics and estimation
methods to three data sets: LHON, NIDDM, and HTN.
For LHON, we have found strong evidence of mtDNA-
mutation involvement, and almost all the pedigrees have
disease that may be due to mtDNA mutations. For
NIDDM and HTN, we have also found strong evidence
of mtDNA-mutation involvement. For NIDDM, we have
estimated the fraction of pedigrees with disease due to
mtDNA mutations to be ∼22% (95% CI 6%–38%). For
HTN, we have estimated the fraction of pedigrees with
disease potentially due to mtDNA mutations to be
∼55% (95% CI 45%–65%). Thus, further studies of
the mtDNA-mutation involvement in NIDDM and
HTN are warranted.
Although the proposed class of tests can circumvent
some confounding factors, factors other than mtDNA-
mutation involvement could still give significant results
for our tests. Intrauterine effects, differential influence
from mothers and fathers, and other gene-environment
factors may all contribute to the statistics. These factors
must be excluded before we confirm mtDNA-mutation
involvement.
In the present article, we have considered only the
heterogeneity model. The score function that we have
proposed may not be good for the testing of mtDNA-
mutation involvement if the disease is not heteroge-
neous. Other score functions are needed in the study of
diseases that involve interactions between nuclear and
mtDNA mutations. This is a topic of further research.
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